Subscribe
shutterstock_1803358558_rafapress
rafapress / Shutterstock.com
10 December 2020AmericasRory O'Neill

Tris blocks Actavis’ ADHD generic

New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder (ADHD) drug Quillivant XR (methylphenidate).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit rejects ADHD generic drug challenge
8 July 2022   A major generic pharma company has failed to undo patents related to the oral suspension Quillivant XR.
Americas
Number of pay-for-delay deals remains low, says FTC
7 December 2020   The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission.
Americas
Judge gives initial approval to Actavis $20m antitrust deal
15 September 2020   A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
Federal Circuit rejects ADHD generic drug challenge
8 July 2022   A major generic pharma company has failed to undo patents related to the oral suspension Quillivant XR.
Americas
Number of pay-for-delay deals remains low, says FTC
7 December 2020   The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission.
Americas
Judge gives initial approval to Actavis $20m antitrust deal
15 September 2020   A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.

More on this story

Americas
Federal Circuit rejects ADHD generic drug challenge
8 July 2022   A major generic pharma company has failed to undo patents related to the oral suspension Quillivant XR.
Americas
Number of pay-for-delay deals remains low, says FTC
7 December 2020   The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission.
Americas
Judge gives initial approval to Actavis $20m antitrust deal
15 September 2020   A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?